Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Earlier roles on record: CEO, Chairman and Board Member at BioRestorative Therapies, Inc. (BRTX) until July 13, 2026. BioRestorative Therapies, Inc. reported in an 8-K filed July 16, 2026 that Lance Alstodt resigned as director, effective July 13, 2026. BioRestorative Therapies, Inc. reported in an 8-K filed July 16, 2026 that Lance Alstodt resigned as Chairman of the Board, effective July 13, 2026. BioRestorative Therapies, Inc. reported in an 8-K filed July 16, 2026 that Lance Alstodt resigned as President, Chief Executive Officer and Chairman of the Board, effective July 13, 2026. The proxy statement of BioRestorative Therapies, Inc. reports total compensation of $1,314,583 for Lance Alstodt in fiscal 2024, including a base salary of $539,583. Disclosed compensation is on record for 6 fiscal years. Lance Alstodt has spoken on 5 earnings calls across 1 company, most recently for BioRestorative Therapies, Inc. on November 12, 2025.
“On July 13, 2026, the Company received notices of resignation from (i) Lance Alstodt, as President, Chief Executive Officer and Chairman of the Board and, by the terms of his notice, from each other position he held as an officer or director of the Company”
“On July 13, 2026, the Company received notices of resignation from (i) Lance Alstodt, as President, Chief Executive Officer and Chairman of the Board and, by the terms of his notice, from each other position he held as an officer or director of the Company”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2020-11-16–2026-07-13
2020-11-16–2026-07-13
2020-01-01–2026-07-13
Start not stated–2026-07-13
Recorded roles and call appearances connecting this person to public companies.
CEO, Chairman, Board Member
2020-01-01–2026-07-13
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | BioRestorative Therapies, Inc. (BRTX) | Chief Executive Officer | $539,583 | $1,314,583 |
| 2023 | BioRestorative Therapies, Inc. (BRTX) | Chief Executive Officer | $479,167 | $1,254,167 |
| 2022 | BioRestorative Therapies, Inc. (BRTX) | Chief Executive Officer | $400,000 | $452,364 |
| 2021 | BioRestorative Therapies, Inc. (BRTX) | Chief Executive Officer | $275,000 | $21,341,489 |
| 2020 | BioRestorative Therapies, Inc. (BRTX) | Chief Executive Officer | $64,317 | $64,317 |
| 2019 | BioRestorative Therapies, Inc. (BRTX) | Chief Executive Officer | $350,000 | $350,000 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
